Quadrature Capital Ltd Has $2.88 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Quadrature Capital Ltd lessened its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 69.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 156,299 shares of the company's stock after selling 352,312 shares during the period. Quadrature Capital Ltd owned about 0.07% of Hims & Hers Health worth $2,880,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $604,000. Carnegie Investment Counsel purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $5,531,000. Royce & Associates LP lifted its holdings in shares of Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $634,000. Finally, International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $6,790,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HIMS. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price for the company. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Imperial Capital lowered Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $21.43.

Hims & Hers Health Trading Up 8.3 %

Hims & Hers Health stock traded up $2.63 during mid-day trading on Friday, hitting $34.23. 13,423,961 shares of the company's stock were exchanged, compared to its average volume of 9,906,611. The stock has a market cap of $7.48 billion, a P/E ratio of 76.23 and a beta of 1.25. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02. The stock has a 50 day moving average of $23.21 and a two-hundred day moving average of $20.36.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) earnings per share. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 45,767 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,094,354.95. This trade represents a 40.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anja Manuel bought 4,000 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average price of $26.94 per share, with a total value of $107,760.00. Following the purchase, the director now owns 4,000 shares of the company's stock, valued at $107,760. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 974,495 shares of company stock valued at $22,548,139. 17.71% of the stock is owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.